New MIMS table on GLP-1 agonists for the treatment of type II diabetes

Available online and in upcoming June print issue of MIMS, the table covers dosing frequency, cost per 28 days, suitability for monotherapy, and possible treatment combinations with metformin, pioglitazone, sulfonylureas, SGLT2 inhibitors and insulin. CV benefits are also noted.


Monthly Index of Medical Specialities